Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] New pathways of treatment for psoriatic arthritis

Psoriatic arthritis occurs in up to 30% of patients with psoriasis.1 The prevalence of psoriasis varies geographically, ranging between 1% and 3% of the population, depending on genetic variation.2 Since the discovery of the cytokine interleukin 17A in 1993, and the subsequent discovery of one of the key cells that produce interleukin 17A and related cytokines, the T-helper-17 cell, in 2005,3 this pathway has been a focus of research in the pathogenesis of psoriasis and closely related conditions, psoriatic arthritis and spondyloarthritis.